Day Zero Diagnostics (DZD) is developing a new class of diagnostic that enables a physician to switch from broad spectrum antibiotic therapy to a targeted antibiotic in 5 hours rather than the 2-5 days that it typically takes today. Unlike other molecular diagnostics that can only detect a handful of specific targets, DZD uses the entire genomic sequence and our proprietary Keynome™ algorithm to identify a comprehensive range of bacterial pathogens and their resistance characteristics within hours.
The system includes a benchtop analyzer combined with proprietary single-use sample preparation cartridges. DZD starts with the same clinical samples that are typically sent to the microbiology lab. The system isolates and enriches bacterial DNA, enabling next generation sequencing without the need to wait for culture. The resulting genomes are then analyzed using a cloud-based analytics platform, allowing physicians to treat the patient with the right antibiotic in hours, rather than days.
DZD was founded in May 2016 and is currently a development stage company. With $3.5M in total funds raised, DZD is targeting the delivery of a prototype in 2018.